# Optimisation of the patient for Heart Transplantation

DR SARAH FITZSIMONS TRANSPLANT CARDIOLOGIST

## CHD AND TRANSPLANTATION

CHD patients are 3% of HT recipient population

Prevalence of HT has increased 40% in CHD population since 1999

- No established prognostic markers to help guide listing
- More likely to die on waiting list
  - Increased incidence of sudden death and HF death
  - Lower priority
  - Donor issues
  - Less likely to get mechanical support 3 vs 17%
  - Increased need for multi-organ transplantation
- Higher peri-operative mortality
- 2x risk of mortality in the first year
- Better long term survival (median 18 years)

# CRITERIA FOR HEART TRANSPLANTATION

- Stage D HF refractory to medical therapy with no alternative surgical options
- CHD with near sudden death or life-threatening refractory arrhythmias
- Reactive pulmonary HTN & risk of developing fixed PVR in near future
- Paediatric
  - Growth failure
  - Severe stenosis/atresia of coronary arteries
  - Cyanosis non-ameanable to surgery
  - Protein losing enteropathy

# TRANSPLANT ASSESSMENT

### **Clinical assessment (Tx cardiologist)**

- Severity of heart failure
- Other medical problems
- Understanding of transplant process
- Desire for transplantation
- Contra-indications to heart transplant

### Investigations

- Blood tests
- Echocardiogram
- Radiology (CXR, abdominal ultrasound, others as indicated)
- Cardiopulmonary exercise test
- Right and left heart catheter

### **Psychosocial assessment**

- Support
- Vices
- Ability to engage with team/report problems/take medications

### **Combined meeting**

- Cardiologists
- Cardiac surgeons
- Transplant coordinators
- Physiotherapists
- Psychologists/psychiatrist
- Social worker
- Dietician

# GOALS OF MANAGEMENT ON ACTIVE WAITING LIST

- Optimise Cardiac Function
  - Identify and Manage Deterioration
- Address co-morbidities e.g. obesity, poor nutrition
- Identify and Address Psychosocial risk factors for poor outcomes
- Identify Immunosuppressive Risks


# OPTIMISING CARDIAC FUNCTION

- Standard heart failure therapy
  - Diuretics
  - ACE-inhibitor
  - B-Blocker
  - Spironolactone
  - (Entresto)
  - CRT
  - ICD
- Address exacerbating factors
  - E.g. Iron Deficiency


•When this fails, what next?

# MECHANICAL SUPPORT

- Should be considered when:
  - Clinical deterioration
  - 'Bridge to Decision'
    - Potentially reversible or treatable contra-indications eg. PHTN, obesity
  - Adequate ability and support to manage device







# MECHANICAL SUPPORT

### **CONTRA-INDICATIONS**

- Infection active systemic
- Compromised haemostasis
  - Bleeding disorders
- Significant AR
- Severe RV dysfunction (relative)
- Complex CHD (relative)
- Psychosocial contra-indication

### COMPLICATIONS

- Bleeding
  - Up to 40% have GI bleeding
  - Infection
    - Driveline 20 60%
  - Stroke
    - More common in women
  - Pump Thrombosis
  - AR
  - Arrhythmia
    - Often VT improves post LVAD

# MCS AND ACHD

- "Simple' pathology can be addressed at the time e.g. ASD closure
- Mostly case reports in complex disease
- Case series in congenitally corrected transposition of the great vessels
  - 3 patients
  - Heart Mate II Device
  - All successfully implanted
- Most recent guidelines recommends:
  - 1) Need assessment of full cardiac morphology (including location of great vessels, shunts, and collateral vessels, assessed before MCS)
  - 2) For non- MCS candidates assessment for total heart replacement strategies is recommended important.
  - 3) A multi-institutional MCS single-ventricle registry that better defines selection criteria should be established

# MECHANICAL SUPPORT

### CASE ONE

- 43yr old male
- Chemotherapy induced cardiomyopathy

### NHYA II-III

RHC:		Post nitroprusside
MPA	44	25
PW	20	13
TPG	24	12
PVR	7.81	3.02
CO	3.2	4.3

### **CASE TWO**

- 60yr old male
- Ischaemic cardiomyopathy
- Rapid decline in function
  - Cardiac cachexia
  - NYHA IV
- Blood Group B

# AMBULATORY INOTROPES

<ul> <li>1984 1x case report with Dobutamine</li> </ul>
<ul> <li>1994 bridge to transplant</li> <li>33 patients</li> <li>Mean duration 4 months</li> </ul>
<ul> <li>Advantages:</li> <li>Patient freedom</li> <li>Cost</li> <li>Improved symptoms and clinical parameters</li> </ul>

• No operation

### •Disadvantages

- Catheter infection, thrombosis
- Arrhythmia
- Tolerance

	PA Mean (mmHg)	PCWP (mmHg)	Cardiac output (L/min)	PVR (Wood units)
Before inotropic therapy	41±3	24±2	3.3±0.2	5.3±0.6
24 hrs post-inotropic therapy	34±3	20±3	5.4±0.7	3.0±0.5
3–9 months post inotropic therapy	28±3	18±1	4.6±0.2	2.5±0.5

PA, Pulmonary artery; PCWP, pulmonary capillary wedge pressure; PVR, pulmonary vascular resistance

European Journal of Heart Failure: Vol 3(5), 2001 601-610

# AMBULATORY INOTROPES

- CASE ONE:
  - 52 year old man
  - Familial dilated cardiomyopathy
    - LVEF 23%
    - NYHA III
    - 4 admissions requiring levosimendan in 4 months prior to assessment
  - Comorbidities: DM, HTN, Obesity
  - 11/2014: Accepted onto the active transplant waiting list
  - 07/2015: Considered for LVAD. Pt declined
    - 4 further admissions with decompensated HF & renal failure in the following year
  - 07/2015: Ambulatory inotropes started
  - 04/2016: Cardiac Transplant

# IDENTIFYING PSYCHOSOCIAL FACTORS

### "BEST INDICATOR OF FUTURE BEHAVIOUR IS PAST BEHAVIOUR"

		Absolute	Relative
Psychopathology	current		*
	history		*
Dementia/Cognitive Impairment		<ul> <li>Moderate to Severe</li> </ul>	× - Mild
Learning Disability			×
Personality Disorder			*
Adherence/motivation		*	
Suicide attempts	recent		*
	multiple	×	
	history		×

### IDENTIFYING PSYCHOSOCIAL FACTORS

		Absolute	Relative
Substance Abuse	nicotine	×	
(current v previous)	alcohol	×	
	illegal/street	×	
Criminal behaviour/anti- social behaviour			×
Attitudes to Tx			×
Lack/instability of support		×	
Difficulty dealing with medical procedures			×

### INTERVENTION-ADHERENCE

No longer accept it is the responsibility of the patient – it is the responsibility of everyone

### INTERVENTION

Trauma-focused cognitive-behavioural therapy (CBT)



- Education to normalise reactions
- Distress tolerance for heightened emotions
- Cognitive restructuring to reduce frightening thoughts
- Techniques to create confidence and expectancy of recovery



# IDENTIFY RISK FOR IMMUNOSUPPRESSION

- Test for Communicable Disease
  - Influenza
  - HPV <45yrs</p>
  - Tetanus, Diptheria, Pertussis
  - Pneumococcal (1 &2)
  - Meningococcal 2
  - Haemophilus Influenzae
  - MMR
  - Hepatitis A & B
  - VZV
- Desensitisation for Reactive Antibodies